Acknowledging that the restoration of SMARCB1 function is likely the primary therapeutic opportunity in ES, in the paragraphs to follow we discuss other therapeutic opportunities related to consistent alterations in other signaling pathways that may also contribute to the pathogenesis of ES. The gene discussed is SMARCB1; the disease is epithelioid sarcoma.